Takaaki Fujii1, Shoko Tokuda2, Yuko Nakazawa2, Sasagu Kurozumi2, Sayaka Obayashi2, Reina Yajima2, Ken Shirabe2. 1. Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan ftakaaki@gunma-u.ac.jp. 2. Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.
Abstract
BACKGROUND/AIM: This study aimed to investigate the progression type of metastatic breast cancer (MBC) in patients undergoing eribulin chemotherapy. MATERIALS AND METHODS: We retrospectively investigated the cases of 66 consecutive patients with MBC who underwent eribulin chemotherapy. RESULTS: A total of 15 patients (22.7%) received eribulin as a 3rd-line or later treatment, and 17 (25.8%) received eribulin as a 1st-line treatment. The overall response was complete response in 0 (0%), partial response in 15 (22.7%), stable disease in 27 (40.9%), and progressive disease in 24 (36.4%) patients. By the time of data cut-off, time to treatment failure (TTF) events had been observed in 60 patients (90.9%), among whom, 15 (25%) had disease progression due to NM, and 45 (75%) had disease progression due to PL. In the regimen before eribulin administration, among 49 patients, 24 (49.0%) had disease progression due to NM. Luminal-type patients and those with triple-negative breast cancer exhibited a similar tendency, i.e., the rate of NM was lower in the patients treated with eribulin. The rate of NM was lower in the patients treated with eribulin in the 1st-line setting than that in patients treated with eribulin as a later treatment. CONCLUSION: Eribulin has a potential antitumor mechanism to prevent new metastasis. Eribulin may be effective against both the epithelial-mesenchymal transition (EMT) process and new metastasis. Copyright
BACKGROUND/AIM: This study aimed to investigate the progression type of metastatic breast cancer (MBC) in patients undergoing eribulin chemotherapy. MATERIALS AND METHODS: We retrospectively investigated the cases of 66 consecutive patients with MBC who underwent eribulin chemotherapy. RESULTS: A total of 15 patients (22.7%) received eribulin as a 3rd-line or later treatment, and 17 (25.8%) received eribulin as a 1st-line treatment. The overall response was complete response in 0 (0%), partial response in 15 (22.7%), stable disease in 27 (40.9%), and progressive disease in 24 (36.4%) patients. By the time of data cut-off, time to treatment failure (TTF) events had been observed in 60 patients (90.9%), among whom, 15 (25%) had disease progression due to NM, and 45 (75%) had disease progression due to PL. In the regimen before eribulin administration, among 49 patients, 24 (49.0%) had disease progression due to NM. Luminal-type patients and those with triple-negative breast cancer exhibited a similar tendency, i.e., the rate of NM was lower in the patients treated with eribulin. The rate of NM was lower in the patients treated with eribulin in the 1st-line setting than that in patients treated with eribulin as a later treatment. CONCLUSION:Eribulin has a potential antitumor mechanism to prevent new metastasis. Eribulin may be effective against both the epithelial-mesenchymal transition (EMT) process and new metastasis. Copyright
Authors: Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves Journal: Lancet Date: 2011-03-02 Impact factor: 79.321
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Jennifer A Smith; Leslie Wilson; Olga Azarenko; Xiaojie Zhu; Bryan M Lewis; Bruce A Littlefield; Mary Ann Jordan Journal: Biochemistry Date: 2010-02-16 Impact factor: 3.162
Authors: Peter A Kaufman; Ahmad Awada; Chris Twelves; Louise Yelle; Edith A Perez; Galina Velikova; Martin S Olivo; Yi He; Corina E Dutcus; Javier Cortes Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: T Yoshida; Y Ozawa; T Kimura; Y Sato; G Kuznetsov; S Xu; M Uesugi; S Agoulnik; N Taylor; Y Funahashi; J Matsui Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640
Authors: Chris Twelves; Javier Cortes; Linda Vahdat; Martin Olivo; Yi He; Peter A Kaufman; Ahmad Awada Journal: Breast Cancer Res Treat Date: 2014-11-08 Impact factor: 4.872